Vertex Pharmaceuticals (NASDAQ:VRTX) has established a wholesale price of $23,896 per 28-day pack of just-approved Trikafta (elexacaftor/tezacaftor and ivacaftor). The cystic fibrosis (CF) med will cost ~$311.5K per year.
Considering the earlier-than-expected FDA nod, the
company has increased its 2019 CF product revenue guidance to $3.70B –
3.75B from $3.60B – 3.70B.
Shares will resume trading at 4:20 pm ET.
Update: Shares are up 1% on resumption of trade.
https://seekingalpha.com/news/3507453-vertex-pharmas-trikafta-cost-311k-per-year
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.